NRG1 and colorectal carcinoma: In the RAS pathway, NRG1 and other EGFR ligands were previously found to play a major role in conferring primary cetuximab resistance in CRC pre-clinical models, although a correlation between NRG1 expression and NRG1 amplification was not reported36.